Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy

• US 6,416,531 B2
• Filed: 06/24/1998
• Issued: 07/09/2002
• Est. Priority Date: 06/24/1998
• Status: Expired due to Term

• Current Assignee: Light Sciences Oncology, Inc.
• Original Assignee: Light Sciences Corporation
• Inventors: Chen, James C.
• Primary Examiner(s): Shay, David M.
• Application Number:
  US09/103,761
• Publication Number:
  US 20020010500A1
• Time in Patent Office: 1,476 Days
• Field of Search: 606/2, 606/3-19, 128/898, 607/88-96, 607/98-101, 604/20
• US Class Current: 607/89
• CPC Class Codes: A61B 2018/2211 Plurality of fibres
• CPC Class Codes: A61B 2018/2261 with scattering, diffusion or dispersion of light
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body
• CPC Class Codes: A61N 5/062 Photodynamic therapy, i.e. excitation of an agent

Abstract

Light is administered during photodynamic therapy (PDT) for an extended period of time at a plurality of sites distributed within the abnormal tissue of a tumor. A clinical study has shown that a substantially greater volume of abnormal tissue in a tumor is destroyed by the extended administration of light therapy from a plurality of probes than would have been expected based upon the teaching of the prior art. In this process, a plurality of light emitting optical fibers or probes are deployed in a spaced-apart array. After a photoreactive agent is absorbed by the abnormal tissue, the light therapy is administered for at least three hours. The greater volume of necrosis in the tumor is achieved due to one or more concomitant effects, including: the inflammation of damaged abnormal tissue and resultant immunological response of the patient'"'"'s body; the diffusion and circulation of activated photoreactive agent outside the expected fluence zone, which is believed to destroy the abnormal tissue; a retrograde thrombosis or vascular occlusion outside of the expected fluence zone; and, the collapse of the vascular system that provides oxygenated blood to portions of the tumor outside the expected fluence zone. In addition, is possible that molecular oxygen diffusing and circulating into the expected fluence zone is converted to singlet oxygen during the extended light therapy, causing a gradient of hypoxia and anoxia that destroys the abnormal tissue outside the expected fluence zone.

Claims

1. A method for destroying abnormal tissue in a tumor within a patient'"'"'s body using an extended light therapy that directly applies light to less than all of the abnormal tissue in the tumor, comprising the steps of:

(a) providing a plurality of light emitting probes, each light emitting probe being capable of emitting light having a characteristic emission waveband and being adapted to be at least partially inserted into said tumor, light emitted by each light emitting probe generating a fluence zone comprising a volume of tissue surrounding the light emitting probe into which light emitted by the light emitting probe penetrates along a direct path, light emitted by each light emitting probe further inducing at least one concomitant effect that generates a necrotic zone associated with each fluence zone when a corresponding light emitting probe emits light for an extended period of time, each necrotic zone extending substantially beyond the associated fluence zone;

(b) determining a desired treatment zone, said desired treatment zone comprising a portion of said tumor that contains substantially all abnormal tissue that will desirably be destroyed by the extended light therapy and at least one concomitant effect associated with the extended light therapy;

(c) administering a photoreactive agent to the abnormal tissue of the tumor, said photoreactive agent having a characteristic light absorption bandwidth and being preferentially absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body;

(d) implanting said plurality of light emitting probes in a spaced-apart array within said tumor, said spaced-apart array defining a pattern of the plurality of light emitting probes selected to directly apply light to less than all of the abnormal tissue, and selected such that a union of each necrotic zone associated with an implanted light emitting probe substantially corresponds to said treatment zone;

(e) activating said plurality of light emitting probes to administer light to the abnormal tissue within the fluence zone around each light emitting probe;

(f) continuing to administer the light emitted by the light emitting probes to the abnormal tissue for at least three hours in carrying out the extended light therapy, said light destroying abnormal tissue within each fluence zone by activating the photoreactive agent absorbed thereby; and

(g) destroying abnormal tissue that is within the treatment zone but substantially beyond the fluence zone around each light emitting probe, by inducing at least one concomitant effect based upon the extended light therapy, a volume of said treatment zone being substantially greater than a combined volume of the fluence zones around each of the plurality of light emitting probes.

2. A method for destroying abnormal tissue in a tumor within a patient'"'"'s body using an extended light therapy that directly applies light to less than all of the abnormal tissue in the tumor, comprising the steps of:

(a) providing a plurality of light emitting probes, each light emitting probe being capable of emitting light having a characteristic emission waveband and being adapted to be at least partially inserted into said tumor, light emitted by each light emitting probe generating a fluence zone comprising a volume of tissue surrounding the light emitting probe into which light emitted by the light emitting probe penetrates along a direct path;

(b) administering a photoreactive agent, said photoreactive agent having a characteristic absorption waveband corresponding to the characteristic emission waveband of the plurality of light emitting probes and being preferably absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body;

(c) implanting said plurality of light emitting probes in a spaced-apart array within said tumor, said spaced-apart array defining a pattern of the plurality of light emitting probes selected to produce at least one concomitant effect that will substantially improve an effectiveness of the extended light therapy, said pattern providing a plurality of non overlapping fluence zones in which light emitted by the plurality of probes is directly applied to less than all of the abnormal tissue in the tumor;

(d) activating said plurality of light emitting probes to administer light to the abnormal tissue within each fluence zone around each light emitting probe;

(e) continuing to administer the light emitted by the light emitting probes to the abnormal tissue for at least three hours in carrying out the extended light therapy, said light destroying abnormal tissue within each fluence zone by activating the photoreactive agent absorbed thereby; and

(f) destroying abnormal tissue that is within a desired necrotic zone but substantially beyond the fluence zone around each light emitting probe, by inducing said at least one concomitant effect based upon the pattern in which the plurality of light emitting probes are implanted in the tumor, a volume of the necrotic zone being substantially greater than a combined volume of the fluence zones around each of the plurality of light emitting probes.

3. A method for destroying abnormal tissue in a tumor within a patient'"'"'s body using an extended light therapy, such that a minor portion of the abnormal tissue destroyed is directly penetrated by light, and a major portion of the abnormal tissue destroyed is not directly penetrated by light, comprising the steps of:

(a) providing a plurality of light emitting probes, each light emitting probe being capable of emitting light having a characteristic emission waveband, being adapted to be at least partially inserted into said tumor, and being capable of generating a fluence zone comprising a region of tissue in said tumor into which light emitted by the light emitting probe penetrates along a direct path;

(b) administering a photoreactive agent, said photoreactive agent being preferentially absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body and having a characteristic light absorption waveband matching said characteristic emission waveband of the plurality of light emitting probes;

(c) implanting said plurality of light emitting probes into said tumor in a spaced-apart array defining a selected pattern, said pattern being selected such that the minor portion of said abnormal tissue within said tumor is within fluence zones produced around the plurality of light emitting probes, and the major portion of said abnormal tissue is not directly penetrated by light emitted from any of said plurality of light emitting probes, said pattern being further selected to induce a concomitant effect that results in abnormal tissue necrosis beyond an extent of each individual fluence zone;

(d) activating said plurality of light emitting probes;

(e) directing the light from the plurality of light emitting probes in a predefined direction, thereby administering light to a defined portion of the tumor, the defined portion including at least some of the abnormal tissue disposed within the minor portion, to limit administration of the photodynamic therapy to said defined portion of the tumor;

(f) continuing the administration of light to the abnormal tissue in the defined portion of the tumor for an extended treatment period in excess of three hours, said light destroying abnormal tissue within the defined portion of the tumor by activating the photoreactive agent absorbed thereby; and

(g) destroying abnormal tissue that is within said major portion of said abnormal tissue, by inducing at least one concomitant effect, thereby destroying the abnormal tissue within said major portion as a result of inducing said at least one concomitant effect.

4. A method for destroying abnormal tissue in a tumor within a patient'"'"'s body using an extended light therapy that directly applies light to less than all of the abnormal tissue in the tumor, comprising the steps of:

(a) providing a plurality of light emitting probes, each light emitting probe being capable of emitting light having a characteristic emission waveband and being adapted to be at least partially inserted into said tumor, light emitted by each light emitting probe generating a fluence zone comprising a volume of tissue surrounding the light emitting probe into which light emitted by the light emitting probe penetrates along a direct path;

(b) administering a photoreactive agent, said photoreactive agent having a characteristic absorption waveband corresponding to the characteristic emission waveband of the plurality of light emitting probes and being preferably absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body;

(c) implanting said plurality of light emitting probes in a spaced-apart array within said tumor, said spaced-apart array defining a pattern of the plurality of light emitting probes selected to produce at least one concomitant effect that will substantially improve an effectiveness of the extended light therapy, said pattern providing a plurality of fluence zones in which light emitted by the plurality of probes is directly applied to less than all of the abnormal tissue in the tumor, said pattern comprising a central core section into which there is substantially no direct light penetration;

(d) activating said plurality of light emitting probes to administer light to the abnormal tissue within each fluence zone around each light emitting probe;

(e) continuing to administer the light emitted by the light emitting probes to the abnormal tissue for at least three hours in carrying out the extended light therapy, said light destroying abnormal tissue within each fluence zone by activating the photoreactive agent absorbed thereby; and

(f) destroying abnormal tissue that is within a desired necrotic zone but substantially beyond the fluence zone around each light emitting probe, by inducing at least one concomitant effect based upon the pattern in which the plurality of light emitting probes are implanted in the tumor, a volume of the necrotic zone being substantially greater than a combined volume of the fluence zones around each of the plurality of light emitting probes.

5. The method of claim 4, wherein said spaced-apart array comprises a plurality of overlapping fluence zones.

6. The method of claim 4, wherein said spaced-apart array comprises a plurality of non overlapping fluence zones.

7. The method of claim 4, wherein the step of activating said plurality of light emitting probes comprises the step of administering light from at least one light source included on each of the plurality of light emitting probes.

8. The method of claim 4, wherein the step of implanting said plurality of light emitting probes further comprises the step of selecting a pattern that enables abnormal tissue within the desired necrotic zone to be destroyed using as few light emitting probes as possible.

9. The method of claim 8, further comprising the step of selecting said plurality of light emitting probes such that light from each of said plurality of probes penetrates the tumor in the treatment zone to a depth that is not more than about 3 cm.

10. The method of claim 8, wherein the step of activating said plurality of light emitting probes comprises the step of delivering light to the plurality of light emitting probes through a plurality of optical fibers from a source that is external to the patient'"'"'s body.

11. The method of claim 8, further comprising the steps of:

(a) emitting light into the tumor in a first direction from each of the plurality of probes, said first direction being determine relative to each probe from which the light is emitted and not necessarily identical for each probe;

(b) terminating light emission into the tumor in the first direction; and

(c) emitting light into the tumor in a second direction from each of the plurality of probes, said second direction being substantially different from the first direction for each of the probes from which the light is emitted.

12. The method of claim 11, wherein the step of emitting light into the tumor in the first direction comprises the step of emitting light toward a perimeter of the tumor, and the wherein the step of emitting light into the tumor in the second direction comprises the step of emitting light toward an interior of the tumor, light emitted in the first direction causing destruction of the abnormal tissue toward the perimeter of the tumor from each probe, which improves an efficacy with which the light emitted in the second direction destroys the abnormal tissue.

13. A method for destroying abnormal tissue in a tumor within a patient'"'"'s body using an extended light therapy, such that a minor portion of the abnormal tissue destroyed is directly penetrated by light, and a major portion of the abnormal tissue destroyed is not directly penetrated by light, comprising the steps of:

(a) providing a plurality of light emitting probes, each light emitting probe being capable of selectively emitting light having a characteristic emission waveband in at least one of a first predefined direction and a second predefined direction, each light emitting probe being adapted to be at least partially inserted into said tumor, and each light emitting probe being capable of generating a fluence zone comprising a region of tissue in said tumor into which light emitted by the light emitting probe penetrates along a direct path;

(b) administering a photoreactive agent, said photoreactive agent being preferentially absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body and having a characteristic light absorption waveband matching said characteristic emission waveband of the plurality of light emitting probes;

(c) implanting said plurality of light emitting probes into said tumor in a spaced-apart array defining a selected pattern, said pattern being selected such that the minor portion of said abnormal tissue within said tumor is within fluence zones produced around the plurality of light emitting probes, and the major portion of said abnormal tissue is not directly penetrated by light emitted from any of said plurality of light emitting probes, said pattern being further selected to induce a concomitant effect that results in abnormal tissue necrosis beyond an extent of each individual fluence zone;

(d) activating said plurality of light emitting probes in an alternating fashion, such that light is only administered in one of the first and the second predefined directions at a time, thereby administering light to the abnormal tissue disposed within the minor portion comprising the fluence zones around each activated light emitting probe;

(e) continuing the administration of light to the abnormal tissue in the minor portion for an extended treatment period in excess of three hours, such that light is administered in both the first and second predefined directions, said light destroying abnormal tissue within the minor portion comprising the fluence zones by activating the photoreactive agent absorbed thereby; and

(f) destroying abnormal tissue that is within said major portion of said abnormal tissue, by inducing said at least one concomitant effect, thereby destroying the abnormal tissue within said major portion as a result of inducing said at least one concomitant effect.

14. The method of claim 13, wherein said spaced-apart array comprises a central core section into which there is substantially no direct light penetration.

15. The method of claim 13, wherein said selected pattern comprises a plurality of overlapping fluence zones.

16. The method of claim 13, wherein said selected pattern comprises a plurality of non overlapping fluence zones.

17. The method of claim 13, wherein said selected pattern comprises a central core volume of abnormal tissue that is devoid of any fluence zone.

18. The method of claim 13, wherein the step of administering light to the abnormal tissue comprises the step of producing the light with at least one light source on each of the plurality of light emitting probes.

19. The method of claim 13, wherein the step of administering light to the abnormal tissue comprises the steps of providing a source of light that is external to the patient'"'"'s body and coupling the source of light to each of the plurality of light emitting probes by a different one of a corresponding plurality of optical fibers.

20. The method of claim 13, wherein the step of providing a plurality of light emitting probes comprises the step of providing a plurality of spaced-apart light sources within each of the plurality of light emitting probes, each spaced-apart light source being capable of selectively emitting light having a characteristic emission waveband in at least one of the first predefined direction and the second predefined direction.

21. The method of claim 13, wherein the plurality of probes are transcutaneously inserted into the tumor.

22. The method of claim 21, further comprising the step of energizing the plurality of probes from an external source of power by transcutaneous transfer of energy.

23. The method of claim 13, further comprising the step of directing the light from the plurality of light emitting probes so as to limit administration of the photodynamic therapy to a defined portion of the tumor.

24. The method of claim 23, wherein the step of providing comprises the step of providing at least one light emitting probe having a reflective surface on one side of the light emitting probe, thereby limiting administration of the light to a direction opposite said reflective surface.

25. A method for destroying abnormal tissue within a tumor in a patient'"'"'s body using an extended light therapy that directly administers light to only a minor portion of said abnormal tissue, yet results in the destruction of a substantially major portion of said abnormal tissue, comprising the steps of:

(a) administering a photoreactive agent to the abnormal tissue of the tumor, said photoreactive agent having a characteristic light absorption bandwidth and being preferentially absorbed by the abnormal tissue rather than by normal tissue in the patient'"'"'s body;

(b) disposing a plurality of light probes in a generally circular pattern, each light emitting probe comprising at least a first light source capable of producing a first fluence zone, and at least a second light source capable of producing a second fluence zone, to achieve a desired generally circular spaced-apart pattern of light within the abnormal tissue, such that;

(i) each first and second fluence zone corresponds to a penetration depth of the light into the tumor along a direct path of the light emitted by one of said first and second light sources, said light that is emitted having a waveband corresponding to the absorption waveband of the photoreactive agent, a cumulative total of the first and second fluence zones comprising only a minor portion of said abnormal tissue;

(ii) a necrotic zone in the tumor is defined by each of said first and second fluence zones and by an additional distance beyond the penetration depth of the light into the tumor, such that the necrotic zone encompasses a substantial portion of the tumor not penetrated by the light being administered along the direct path and is thus beyond each first and second fluence zone;

(iii) a portion of a vasculature of said tumor servicing at least a portion of said necrotic zone lies within at least one second fluence zone; and

(iv) a periphery of said tumor lies within at least one first fluence zone;

(c) administering the light from said plurality of light emitting probes to the abnormal tissue within each first fluence zone by activating each first light source, thereby directing light toward said periphery but not toward an interior of said tumor, said light activating said photoreactive agent to destroy the abnormal tissue illuminated by the light by providing a photodynamic therapy to each first fluence zone; and

(d) continuing the administration of light from said plurality of light emitting probes to the abnormal tissue within each second fluence zone by activating each second light source, thereby directing light toward the interior of said tumor until a secondary effect is produced in the abnormal tissue beyond the first and second fluence zones, said secondary effect causing necrosis of the abnormal tissue outside each first and second fluence zone, but within said necrotic zone, thereby destroying a substantially major portion of the abnormal tissue with the secondary effect, although directly administering light to only a minor portion of said abnormal tissue, said secondary effect comprising at least one of a vascular collapse, a stasis, and an occlusion within said portion of the vasculature.

26. The method of claim 25, wherein said additional distance is no greater than. 5 centimeters, and wherein the step of disposing the plurality of light emitting probes to achieve a desired pattern further comprises the step of positioning the